Author Affiliations: Institute for Health Policy Studies, University of California, San Francisco (Drs Rennie and Luft); and JAMA, Chicago, Ill (Dr Rennie).
The issue of prescription drug benefits is being hotly debated in the
United States. We can be sure that cost-conscious insurance organizations,
both governmental and commercial, will demand an ever stronger role in deciding
which drugs they pay for and include in managed care formularies. Pharmaceutical
companies can be expected to continue to fund analyses of the cost-effectiveness
of their products, and, as legal and political maneuvering in the United Kingdom,
Canada, and Australia has shown, to continue to bring great political and
legal pressure on the organizations responsible for deciding the relative
merits of their products.1-3
Much of the battle will revolve around measurements of the cost-effectiveness
of new drugs.
Rennie D, Luft HS. Pharmacoeconomic Analyses: Making Them Transparent, Making Them Credible. JAMA. 2000;283(16):2158–2160. doi:10.1001/jama.283.16.2158
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: